In vitro transcription (IVT) is a laboratory technique that produces RNA from a DNA template in a test tube, without using living cells. The reaction combines a DNA template, an enzyme called RNA polymerase, free RNA building blocks (nucleotides), and a buffer solution. Within hours, it can generate large quantities of custom RNA, making it the core manufacturing step behind mRNA vaccines, research tools, and a growing list of RNA-based therapies.
How the Reaction Works
Inside a living cell, transcription is the process of copying a gene’s DNA sequence into an RNA message. In vitro transcription recreates this process in a simplified, controlled setting. You strip the reaction down to its essentials: a piece of DNA carrying the sequence you want, an RNA polymerase enzyme to read it, the four nucleotide building blocks (ATP, GTP, CTP, and UTP), and a buffer that keeps the chemistry stable.
The process follows three stages: initiation, elongation, and termination. During initiation, the RNA polymerase recognizes and binds to a specific short sequence on the DNA called a promoter. This binding bends and opens the double-stranded DNA, exposing the template strand. After the first 3 to 7 nucleotides are joined together, the growing RNA chain pushes against the enzyme, causing it to rotate about 40 degrees. Once roughly 9 to 12 nucleotides have been assembled, a much larger rotation of 220 degrees releases the enzyme from the promoter and locks it into a stable elongation mode. From that point, the polymerase moves steadily along the template, assembling the full-length RNA transcript until it reaches the end of the template and falls off.
Key Ingredients in the Reaction
The most widely used enzyme for IVT is T7 RNA polymerase, originally derived from a virus (bacteriophage T7) that infects bacteria. T7 is popular because it is fast, well understood, and highly specific: it only begins transcription when it encounters its matching T7 promoter sequence. Two related enzymes, SP6 and T3 RNA polymerases, also come from bacteriophages and work the same way with their own promoter sequences, but T7 dominates commercial and research applications. It was the enzyme used to produce the first approved mRNA vaccines.
The DNA template must include the correct promoter sequence upstream of the gene you want to transcribe. Most labs use a circular plasmid (a small loop of DNA grown in bacteria) that has been cut open, or “linearized,” with a restriction enzyme so the polymerase has a defined stopping point. The enzyme BspQI is commonly used for this step. Without linearization, the polymerase can loop around the plasmid and produce unwanted, extra-long RNA or other byproducts.
Beyond polymerase and template, the reaction buffer supplies magnesium ions, which are essential cofactors for the enzyme, along with a controlled pH and salt concentration. The four nucleotide triphosphates serve as raw materials, snapping into the growing RNA chain one at a time according to the template’s instructions.
Adding a Cap for Functional mRNA
If the goal is to produce mRNA that will work inside a cell (as in vaccines or gene therapies), the RNA needs a protective “cap” structure on its front end. This cap mimics what cells naturally add to their own mRNA, and without it, the RNA is quickly destroyed and poorly translated into protein.
Capping can happen during the IVT reaction itself, called co-transcriptional capping, or as a separate enzymatic step afterward. Co-transcriptional capping is simpler because it combines two steps into one, but efficiency varies by method. An older reagent called ARCA typically caps only 34 to 77% of RNA molecules, depending on the sequence context. A newer reagent, CleanCap, achieves 81 to 92% capping efficiency in standard assays, with some batches exceeding 99% when measured by sensitive analytical methods. Enzymatic post-transcriptional capping also routinely reaches above 90%. Higher capping efficiency means more of the final RNA product is functional, which matters enormously at manufacturing scale.
Modified Nucleotides and Why They Matter
One of the breakthroughs that made mRNA vaccines practical was swapping in chemically modified nucleotides during IVT. In the Pfizer-BioNTech and Moderna COVID-19 vaccines, for example, one of the four standard RNA building blocks (uridine) is replaced with a modified version called N1-methylpseudouridine. This single change dramatically reduces the immune system’s tendency to attack the RNA as a foreign invader before it can do its job.
Modified nucleotides also improve RNA stability. Unmodified RNA survives only minutes in blood or other body fluids because enzymes that break down RNA are everywhere. Chemical modifications at the 2′ position of the sugar component, such as adding a fluorine atom or a methyl group, can extend RNA survival from minutes to hours or even days. In one study, an RNA molecule carrying 2′-fluoro and 2′-O-methyl modifications remained intact in blood plasma for over 96 hours, compared to roughly 4 minutes for the unmodified version. Engineered mutant versions of T7 RNA polymerase have been developed specifically to incorporate these modified building blocks more efficiently.
Common Problems and Byproducts
IVT reactions don’t always produce a clean batch of full-length RNA. One persistent challenge is short, truncated fragments. During the initiation phase, before the polymerase locks into its stable elongation mode at around 10 nucleotides, it sometimes falls off the template and releases incomplete snippets. Reducing these abortive products is an active area of enzyme engineering.
Another well-known issue is the formation of double-stranded RNA (dsRNA) byproducts. T7 RNA polymerase can sometimes loop back on itself or use the newly made RNA as a template, generating dsRNA that triggers a strong inflammatory response in cells. Purifying the linearized DNA template before the reaction helps reduce dsRNA formation. Post-reaction purification steps, including chromatography and enzymatic digestion of the DNA template, are standard for removing these contaminants from the final product.
RNase contamination is the other classic failure mode. RNases, the enzymes that degrade RNA, are notoriously stable and present on skin, lab surfaces, and improperly treated reagents. Even trace amounts can destroy an entire batch of RNA within minutes. Labs working with IVT use RNase-free water, dedicated equipment, and gloves at every step to prevent this.
Applications Beyond Vaccines
While mRNA vaccines brought IVT into public awareness, the technique has been a workhorse in molecular biology for decades. Researchers use it to generate labeled RNA probes for detecting specific genes, to produce RNA for structural studies, and to make guide RNAs for CRISPR gene editing. It is also used to synthesize RNA aptamers, short RNA molecules selected to bind tightly to specific targets like proteins or small molecules, which have potential as diagnostic and therapeutic tools.
At industrial scale, IVT is attractive because it is entirely cell-free. Unlike protein-based drugs that require growing large batches of cells, mRNA production needs only purified enzyme, a DNA template, and nucleotides. This makes manufacturing faster to set up and easier to scale, which is part of why mRNA vaccine production could be ramped up so quickly during the COVID-19 pandemic. The same platform can be redirected to a new target simply by changing the DNA template sequence, leaving the rest of the process identical.